Profil
Will Greenleaf is the founder of Protillion Biosciences, Inc. He is also the founder of Epinomics, Inc.
Postes actifs de Will Greenleaf
| Sociétés | Poste | Début |
|---|---|---|
Epinomics, Inc.
 Epinomics, Inc. Packaged SoftwareTechnology Services Epinomics, Inc. provides decoding programming of genome to drive personalized medicine. The company was founded by Paul Giresi, Fergus Chan, Howard Y. Chang and Will Greenleaf and is headquartered in Menlo Park, CA. | Fondateur | - |
Anciens postes connus de Will Greenleaf
| Sociétés | Poste | Fin |
|---|---|---|
Protillion Biosciences, Inc.
 Protillion Biosciences, Inc. BiotechnologyHealth Technology Protillion Biosciences, Inc. is a company based in Burlingame, CA that was founded in 2019 by Will Greenleaf, David R. Walt, and Curtis Layton. The company specializes in commercializing disruptive technology for therapeutic antibody and binder discovery. The company's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run, enabling the identification of better antibody candidates on an exponentially faster timeline compared to current state-of-the-art antibody discovery and optimization techniques that may take months of laborious laboratory procedures executed by highly-skilled practitioners. Curtis Layton has been the CEO since 2019. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Epinomics, Inc.
Epinomics, Inc. Packaged SoftwareTechnology Services Epinomics, Inc. provides decoding programming of genome to drive personalized medicine. The company was founded by Paul Giresi, Fergus Chan, Howard Y. Chang and Will Greenleaf and is headquartered in Menlo Park, CA. | Technology Services |
Protillion Biosciences, Inc.
Protillion Biosciences, Inc. BiotechnologyHealth Technology Protillion Biosciences, Inc. is a company based in Burlingame, CA that was founded in 2019 by Will Greenleaf, David R. Walt, and Curtis Layton. The company specializes in commercializing disruptive technology for therapeutic antibody and binder discovery. The company's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run, enabling the identification of better antibody candidates on an exponentially faster timeline compared to current state-of-the-art antibody discovery and optimization techniques that may take months of laborious laboratory procedures executed by highly-skilled practitioners. Curtis Layton has been the CEO since 2019. | Health Technology |
